Investment Rating - The report maintains an "Overweight" rating for the innovative drug sector, indicating that the industry is expected to outperform the overall market [5][11]. Core Insights - The report emphasizes the long-term investment value of Chinese innovative drugs, highlighting three main supporting logics: innovation upgrades, profitability inflection points, and normalization of outbound business development (BD) [5]. - Chinese biotech companies are demonstrating significant capabilities in global innovation, with notable products emerging in the PD-1/VEGF dual antibody and EGFR/c-MET dual antibody ADC categories [5]. - Leading biotech firms like BeiGene and Innovent Biologics are projected to reach profitability in 2025, suggesting a sustained high growth trajectory for the sector [5]. - The total value of license-out agreements from mainland China to Europe and the US has reached $94.3 billion as of September 2025, significantly surpassing the $51.9 billion recorded for the entirety of 2024 [5]. Summary by Sections Industry Overview - The report discusses the potential impact of a proposed US government draft that aims to limit American pharmaceutical companies from acquiring experimental drugs from China, although the likelihood of this draft being implemented is considered low [5]. - The report argues that even if the US tightens regulations, Chinese biotech can still pursue collaborations with European firms and establish overseas companies to navigate these restrictions [5]. Company Valuations - The report includes a valuation table for key companies in the pharmaceutical and biotech sector, detailing market capitalization, earnings per share (EPS) projections, and price-to-earnings (PE) ratios for 2024 to 2027 [6]. - Notable companies mentioned include: - Hengrui Medicine with a market cap of 453.3 billion yuan and a projected PE ratio of 68.3 for 2024 [6]. - BeiGene with a market cap of 436.5 billion yuan, expected to turn profitable by 2026 [6]. - Innovent Biologics and other firms are also highlighted for their growth potential and market performance [6].

关于核心技术人员退休离任的公告 证券代码：688488 证券简称：艾迪药业 公告编号：2025-050 江苏艾迪药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●江苏艾迪药业集团股份有限公司（以下简称"公司"或"艾迪药业"）核 心技术人员张纪兵先生因达到法定退休年龄提请退休，离任后不再担任公司核心 技术人员。 ●公司与张纪兵先生不存在涉及职务发明的专利权属纠纷或潜在纠纷，其离 任不会影响公司专利权的完整性。 ●张纪兵先生所负责工作已完成交接，公司的生产经营、技术研发等工作均 有序推进，张纪兵先生的离任不会对公司持续经营能力、研发实力、核心竞争力 产生重大不利影响。 一、核心技术人员退休离任的情况 公司核心技术人员张纪兵先生因达到法定退休年龄提请退休，离任后不再担 任公司核心技术人员。张纪兵先生任职期间爱岗敬业，恪尽职守，勤勉尽责，公 司对张纪兵先生为公司发展所做出的贡献表示衷心感谢！ （一）核心技术人员的具体情况 张纪兵，男，中国国籍，无境外居留权，1965 年 8 月出生，毕业于南京 ...

Group 1 - The company will hold an investor briefing on September 16, 2025, from 15:00 to 17:00 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [3][4] - Investors can submit questions from September 9 to September 15, 2025, through the Roadshow Center website or via the company's email [2][5] Group 2 - The briefing aims to provide insights into the company's operating results and financial status for the first half of 2025 [2][3] - Key participants in the briefing will include the company's president, independent directors, financial director, and board secretary [5] - After the briefing, investors can access the main content and outcomes of the meeting on the Shanghai Stock Exchange Roadshow Center [7]

Group 1 - The company, Aidi Pharmaceutical, announced its plan to participate in the 2025 semi-annual Science and Technology Innovation Board performance briefing for the innovative drug industry on September 16, 2025 [2]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-049 江苏艾迪药业集团股份有限公司 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com） ? 会议召开方式：上证路演中心网络文字互动 ? 投资者可于 2025 年 9 月 9 日 （星期二） 至 9 月 15 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ad@aidea.com.cn）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 江苏艾迪药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 16 日（星期 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-049 江苏艾迪药业集团股份有限公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 9 月 9 日 （星期二） 至 9 月 15 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ad@aidea.com.cn）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 江苏艾迪药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年 ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

从艾迪药业十大流通股东角度 截至发稿，吴远怡累计任职时间4年340天，现任基金资产总规模204.78亿元，任职期间最佳基金回报 105.45%， 任职期间最差基金回报-18.82%。 9月3日，艾迪药业涨5.1%，截至发稿，报17.52元/股，成交1.96亿元，换手率2.77%，总市值73.72亿 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，江苏艾迪药业集团股份有限公司位于江苏省扬州市邗江区新甘泉西路69号，成立日期2009年 12月15日，上市日期2020年7月20日，公司主营业务涉及探索、研发和销售创新性化学药物以及人源蛋 白产品。主营业务收入构成为：HIV新药(艾诺米替片)31.96%，药品(尿激酶针剂)19.16%，番泻叶颗粒 13.25%，乌司他丁粗品12.08%，尿激酶粗品10.81%，其他人源蛋白粗品4.18%，HIV新药(艾诺韦林 片)3.92%，药品-其他2.76%，HIV诊断试剂0.80%，蜡样芽孢杆菌片0.54%，其他(补充)0. ...

Core Viewpoint - The company, Eddie Pharmaceuticals, is making significant advancements in the development of HIV treatments, particularly focusing on the new generation of integrase inhibitors and long-acting preventive medications, while also expanding its human protein business. Group 1: HIV Treatment Development - The company has completed a Phase I/IIa clinical study for its new integrase inhibitor, CC017, showing a significant viral load reduction of 2.34 Log10 copies/mL after 10 days of monotherapy, with over 90% of participants achieving complete viral suppression after 18 days of combination therapy [2] - The company reported a 58.49% year-on-year increase in sales revenue for its HIV new drugs, reaching 129 million yuan in the first half of 2025, indicating successful commercialization efforts [3] - The company is actively participating in academic conferences to promote its products and enhance its brand image, while also focusing on patient education and team optimization to improve treatment quality and service processes [3] Group 2: Long-Acting Preventive Medications - The company is accelerating the development of long-acting HIV medications, responding to national strategies for HIV prevention, with two new long-acting drug patents filed and accepted [4] - The market for long-acting medications is expected to grow due to their lower side effects and better privacy, positioning the company to capture a significant share of the pre-exposure prophylaxis (PrEP) market [4] Group 3: Human Protein Business Expansion - The company has established strong relationships with upstream suppliers and is integrating operations following the acquisition of Nanda Pharmaceutical, which has positively impacted its revenue and profitability [6] - The human protein market is growing, with significant advancements in collaboration with Nanda Pharmaceutical, including the approval of new drug applications for innovative human protein products [7] Group 4: Financial Performance - The company's mid-2025 report shows a 100.19% increase in main revenue to 362 million yuan and a 120.23% increase in net profit to 9.19 million yuan [8] - The second quarter of 2025 saw a revenue increase of 86.71% year-on-year, indicating strong financial performance despite some negative net profit figures [8]

格隆汇9月1日｜有投资者在互动平台向艾迪药业提问：2025年H1普药收入增速61%，主要是哪个细分 领域的药需求增速较快？ 艾迪药业回应称，公司普药业务增速较快主要来自于番泻叶颗粒销量的增加，该药品是公司独家品种， 主治泻热行滞，通便，可解决便秘、清肠。 ...